Tumoricidal Property of Normoxia and Hypoxia Cell-Free Lysate ofWharton’s Jelly-Mesenchymal Stem Cells Toward Various CancerCells

Cancer is one of the leading causes of mortality and morbidity throughout the world. Since there are still some problems related to the conventional therapies for cancer treatment, it is critical to explore new more efficient therapy strategies. Mesenchymal Stem Cells (MSCs) are one of powerful tools for tissue engineering for regenerative medicine, as recent research aims to utilize MSCs for anti-cancer treatment. Our previous research demonstrated that Conditioned Medium from Whartons’ Jelly MSCs (WJ-MSCs-CM) significantly lowered cancer proliferation of various cancer cell lines. This research was performed to evaluate the tumoricidal property of cell lysate from WJ-MSCs from normoxia (WJMSCs-norCL) and hypoxia-treated WJMSCs (WJMSCs-hypoCL) on the proliferation of human cancer cells, including cervical (HeLa), liver (HepG2), ovarian (SKOV3) and oral squamous (HSC3) cancer cell lines compared to normal cells including mouse fibroblast (NIH3T3), human Mesenchymal Stem Cells (hMSCs), human fibroblast. The WJMSCs-norCL and WJMSCs-hypoCL have cytotoxic activity, reduce proliferation of various cancer cell lines with minimum inhibitory concentration (IC50) 21.094-95.928 μg mLG1 and no cytotoxic to normal cells with IC50 409, 191-629, 799.738 μg mLG1. The WJMSCs-norCL and WJMSCs-hypoCL inhibit proliferation in various cancer cell lines and are not toxic for normal cells.